Botanix Pharmaceuticals (BOT) Stock Overview
Operates as a commercial dermatology company in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BOT Community Fair Values
Create NarrativeSee what 77 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Botanix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.049 |
| 52 Week High | AU$0.48 |
| 52 Week Low | AU$0.049 |
| Beta | 0.84 |
| 1 Month Change | -55.45% |
| 3 Month Change | -57.39% |
| 1 Year Change | -88.19% |
| 3 Year Change | -51.00% |
| 5 Year Change | -57.39% |
| Change since IPO | 63.33% |
Recent News & Updates
Recent updates
Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. What are the underlying business or industry changes driving this perspective?Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Dec 10
Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?
Mar 21Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Sep 06Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely
Jan 03Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?
Sep 05Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
May 10We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Jan 12We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth
Jul 01We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
Mar 18The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More
Jan 24We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
Nov 30
Shareholder Returns
| BOT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -14.0% | 0.7% | -3.2% |
| 1Y | -88.2% | -11.3% | 11.1% |
Return vs Industry: BOT underperformed the Australian Pharmaceuticals industry which returned -11.3% over the past year.
Return vs Market: BOT underperformed the Australian Market which returned 11.1% over the past year.
Price Volatility
| BOT volatility | |
|---|---|
| BOT Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 9.8% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.2% |
Stable Share Price: BOT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BOT's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Howie McKibbon | www.botanixpharma.com |
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis.
Botanix Pharmaceuticals Limited Fundamentals Summary
| BOT fundamental statistics | |
|---|---|
| Market cap | AU$108.69m |
| Earnings (TTM) | -AU$88.70m |
| Revenue (TTM) | AU$21.92m |
Is BOT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOT income statement (TTM) | |
|---|---|
| Revenue | AU$21.92m |
| Cost of Revenue | AU$8.52m |
| Gross Profit | AU$13.39m |
| Other Expenses | AU$102.10m |
| Earnings | -AU$88.70m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.04 |
| Gross Margin | 61.11% |
| Net Profit Margin | -404.72% |
| Debt/Equity Ratio | 0% |
How did BOT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 16:47 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Botanix Pharmaceuticals Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madeleine Williams | Canaccord Genuity |
| Joseph Pantginis | H.C. Wainwright & Co. |